Screener
PTC Therapeutics PTCT Current Debt
Current Debt at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtCurrent.
The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001070081-26-000012
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Liabilities and stockholders’ deficit | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $313,050 | $381,272 |
| Current portion of long-term debt | 286,937 | 286,631 |
| Deferred revenue | 498 | 2,040 |
| Operating lease liabilities- current | 12,078 | 12,484 |
| Finance lease liabilities- current | 6,000 | 3,000 |
| Liability for sale of future royalties- current | 305,041 | 283,000 |
Item 1. Financial Statements (unaudited)
FAQ
- What is PTC Therapeutics's current debt?
- PTC Therapeutics (PTCT) reported current debt of $286.94M in Q1 2026.
- How has PTC Therapeutics's current debt changed year-over-year?
- PTC Therapeutics's current debt increased by 5585.3% year-over-year, from $5.05M to $286.94M.
- What is the long-term trend for PTC Therapeutics's current debt?
- Over 5 years (2020 to 2025), PTC Therapeutics's current debt has grown at a 195.3% compound annual growth rate (CAGR), from $1.28M to $286.63M.
- What does current debt mean?
- The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.
Ask your AI about PTC Therapeutics's current debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude